Breaking News, Collaborations & Alliances

Mount Sinai, Emergent, and ImmunoTek Form Collaboration

To develop Emergent’s COVID-19 hyperimmune globulin product candidate with U.S. DoD funding.

By: Contract Pharma

Contract Pharma Staff

The Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers are collaborating to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Ra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters